Rocket has pulled an approval application to the FDA, with the biotech considering offloading the asset via external ...

The Trump administration announced Pfizer has agreed to provide all of its medicines at Most Favored Nation (MFN) pricing in ...

Roche and Jazz's combination is now the first and only approved dual maintenance therapy for ES-SCLC, rivaling AZ's Imfinzi ...

With decades of hands-on experience, Sharp’s industry experts reveal their top five recommendations for a timely and ...

Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

The US Food and Drug Administration (FDA) has approved Evita Solutions’ generic form of mifepristone, one of the two ...

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities ...

The clinical success of CRISPR-based treatments is fundamentally dependent on sophisticated gRNA targeting systems that ...

The Massachusetts bioresearch centre expansion is part of AbbVie’s wider ploy to bolster its US operations amid Trump tariff ...

As part of President Trump’s Most Favored Nation (MFN) policy, the company agreed to ensure that US patients are paying less ...